Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
My View
Tags:
Regulation In Vitro Diagnostics Coronavirus COVID-19

Minute Insight: Lumos’ Bacterial-Viral Infection Differentiation Test Flops At FDA

  • News

Executive Summary

Lumos Diagnostics is considering an appeal of the agency’s decision to refuse market clearance for its FebriDX test.

You may also be interested in...



Reducing Antimicrobial Resistance With Rapid Tests

Widespread implementation of rapid diagnostic tests is critical for decreasing antimicrobial resistance. 

Execs On The Move: New Leaders for Vyaire, Nevro, And More In May 2023

An interactive summary of recent executive-level company changes and promotions in the medical device and diagnostics sectors.

Minute Insight: Owlstone Medical’s 'Breath Biopsy' Tech Adopted By US Military

The company will create a handheld version of its FAIMS technology, to be used in rapid testing for transmissible illnesses in combat scenarios.

Table

View full table

Topics

Related Companies

Tags:
Regulation In Vitro Diagnostics Coronavirus COVID-19
Latest Headlines

Abbott Invests Millions In Clinical Trial Diversification Efforts

Cardio Catch-Up: Two Studies Support Boston Scientific’s Subcutaneous ICD

Cardio Catch-Up: Boston Scientific's Next-Gen Watchman FLX Pro Reduces Thrombi Risk In Trials

Cardio Catch-Up: Boston Scientific's Farapulse PFA Shows Short Learning Curve In European Registry

See All
UsernamePublicRestriction

Register

MT145616

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By